Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Treasury Shares (2021 - 2025)

Zevra Therapeutics' Treasury Shares history spans 5 years, with the latest figure at $11.0 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, changed 0.0%, while the annual FY2025 figure was $11.0 million, 0.0% changed from the prior year.
  • Treasury Shares reached $1.6 million in Q4 2025 per ZVRA's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.8 million in Q4 2024 to a low of $320161.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.0 million, with a median of $909953.0 recorded in 2022.
  • Peak YoY movement for Treasury Shares: skyrocketed 167.8% in 2022, then changed 0.0% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $2.8 million in 2021, then surged by 167.8% to $7.5 million in 2022, then surged by 45.74% to $11.0 million in 2023, then changed by 0.0% to $11.0 million in 2024, then changed by 0.0% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Treasury Shares are $11.0 million (Q4 2025), $11.0 million (Q3 2025), and $11.0 million (Q2 2025).